{"title":"AAV8 Vectors","description":"\u003cp\u003eReady-to-use AAV8 vectors for high-efficiency liver, muscle, and heart gene delivery — qPCR-titered and in stock.\u003c\/p\u003e","products":[{"product_id":"aav-null-aav-serotype-8-bhv21500042","title":"AAV-Null (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500042\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167700845,"sku":"SL100832-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167733613,"sku":"SL100832-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500042_aav-null-aav-serotype-8_SL100832.jpg?v=1770796185"},{"product_id":"aav-gfp-aav-serotype-8-bhv21500043","title":"AAV-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500043\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167766381,"sku":"SL100833-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167799149,"sku":"SL100833-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500043_aav-gfp-aav-serotype-8_SL100833.png?v=1770796186"},{"product_id":"scaav-gfp-aav-serotype-8-self-complementary-bhv21500044","title":"scAAV-GFP (AAV Serotype 8, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500044\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167831917,"sku":"SL100833-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167864685,"sku":"SL100833-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500044_scaav-gfp-aav-serotype-8-self-complementary_SL100833-SC.png?v=1770796186"},{"product_id":"aav-cre-aav-serotype-8-bhv21500045","title":"AAV-Cre (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500045\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167897453,"sku":"SL100834-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167930221,"sku":"SL100834-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500045_aav-cre-aav-serotype-8_SL100834.png?v=1770796186"},{"product_id":"scaav-cre-aav-serotype-8-self-complementary-bhv21500046","title":"scAAV-Cre (AAV Serotype 8, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500046\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167962989,"sku":"SL100834-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167995757,"sku":"SL100834-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500046_scaav-cre-aav-serotype-8-self-complementary_SL100834-SC.png?v=1770796187"},{"product_id":"aav-cre-gfp-aav-serotype-8-bhv21500047","title":"AAV-Cre-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500047\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168028525,"sku":"SL100835-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168061293,"sku":"SL100835-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500047_aav-cre-gfp-aav-serotype-8_SL100835.png?v=1770796187"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-8-bhv21500048","title":"AAV-U6-shRNA(scramble)-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500048\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168094061,"sku":"SL100836-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168126829,"sku":"SL100836-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500048_aav-u6-shrna-scramble-gfp-aav-serotype-8_SL100836.png?v=1770796187"},{"product_id":"aav-cag-gfp-aav-serotype-8-bhv21500049","title":"AAV-CAG-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500049\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168159597,"sku":"SL100837-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168192365,"sku":"SL100837-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500049_aav-cag-gfp-aav-serotype-8_SL100837.png?v=1770796188"},{"product_id":"aav-synapsin-gfp-aav-serotype-8-bhv21500050","title":"AAV-Synapsin-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500050\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168225133,"sku":"SL100838-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168257901,"sku":"SL100838-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500050_aav-synapsin-gfp-aav-serotype-8_SL100838.png?v=1770796188"},{"product_id":"scaav-synapsin-gfp-aav-serotype-8-self-complementary-bhv21500051","title":"scAAV-Synapsin-GFP (AAV Serotype 8, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500051\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168290669,"sku":"SL100838-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168323437,"sku":"SL100838-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500051_scaav-synapsin-gfp-aav-serotype-8-self-complementary_SL100838-SC.png?v=1770796188"},{"product_id":"aav-cag-chr2-venus-aav-serotype-8-bhv21500066","title":"AAV-CAG-ChR2-Venus (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChR2-Venus\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500066\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eChR2-Venus is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChR2\u003c\/strong\u003e. A \u003cstrong\u003eVenus + YFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169437549,"sku":"SL100850-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169470317,"sku":"SL100850-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500066_aav-cag-chr2-venus-aav-serotype-8_SL100850.png?v=1770796193"},{"product_id":"aav-mrfp-aav-serotype-8-bhv21500081","title":"AAV-mRFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mRFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500081\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emRFP is the encoded payload for this construct. A \u003cstrong\u003emRFP + RFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mRFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170584429,"sku":"SL100870-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020170617197,"sku":"SL100870-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500081_aav-mrfp-aav-serotype-8_SL100870.png?v=1770796199"},{"product_id":"aav-lacz-aav-serotype-8-bhv21500083","title":"AAV-LacZ (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-LacZ\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500083\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLacZ is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: LacZ-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170715501,"sku":"SL100878-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020170748269,"sku":"SL100878-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500083_aav-lacz-aav-serotype-8_SL100878.png?v=1770796199"},{"product_id":"aav-cag-chief-tdtomato-aav-serotype-8-bhv21500085","title":"AAV-CAG-ChIEF-tdTOMATO (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChIEF-tdTOMATO\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500085\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eChIEF-tdTOMATO is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChIEF\u003c\/strong\u003e. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170846573,"sku":"SL100880-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020170879341,"sku":"SL100880-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500085_aav-cag-chief-tdtomato-aav-serotype-8_SL100880.png?v=1770796200"},{"product_id":"aav-synapsin-cre-gfp-aav-serotype-8-bhv21500088","title":"AAV-Synapsin-Cre-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500088\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171043181,"sku":"SL100883-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171075949,"sku":"SL100883-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500088_aav-synapsin-cre-gfp-aav-serotype-8_SL100883.png?v=1770796201"},{"product_id":"aav-synapsin-cre-aav-serotype-8-bhv21500092","title":"AAV-Synapsin-Cre (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500092\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171272557,"sku":"SL100887-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171305325,"sku":"SL100887-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500092_aav-synapsin-cre-aav-serotype-8_SL100887.png?v=1770796203"},{"product_id":"aav-hsyn-dio-mcherry-aav-serotype-8-bhv21500109","title":"AAV-hSyn-DIO-mCherry (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-hSyn-DIO-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500109\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eDIO-mCherry is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eRecombinase\u003c\/strong\u003e. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003eCre-dependent (DIO\/FLEX)\u003c\/strong\u003e—the transgene is inverted and silenced by default, and flips into the active orientation only in cells expressing Cre recombinase. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003cli\u003eCre-driver dependent expression\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) Cre-driver-negative animals injected with the same DIO vector to confirm absence of leaky expression; (2) driver-positive animals without vector injection to confirm no background from the driver alone; (3) a Cre-expressing positive-control line to validate recombination efficiency; and (4) assay-matched functional or anatomical readouts to confirm payload activity only in driver-positive, vector-injected animals.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172452205,"sku":"SL101120-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172484973,"sku":"SL101120-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500109_aav-hsyn-dio-mcherry-aav-serotype-8_SL101120.png?v=1770796208"},{"product_id":"aav-hsyn-dio-gfp-aav-serotype-8-bhv21500110","title":"AAV-hSyn-DIO-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-hSyn-DIO-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500110\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eDIO-GFP is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eRecombinase\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003eCre-dependent (DIO\/FLEX)\u003c\/strong\u003e—the transgene is inverted and silenced by default, and flips into the active orientation only in cells expressing Cre recombinase. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003cli\u003eCre-driver dependent expression\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) Cre-driver-negative animals injected with the same DIO vector to confirm absence of leaky expression; (2) driver-positive animals without vector injection to confirm no background from the driver alone; (3) a Cre-expressing positive-control line to validate recombination efficiency; and (4) assay-matched functional or anatomical readouts to confirm payload activity only in driver-positive, vector-injected animals.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172517741,"sku":"SL101121-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172550509,"sku":"SL101121-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500110_aav-hsyn-dio-gfp-aav-serotype-8_SL101121.png?v=1770796208"},{"product_id":"aav-mcherry-aav-serotype-8-bhv21500113","title":"AAV-mCherry (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500113\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172714349,"sku":"SL101128-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172747117,"sku":"SL101128-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500113_aav-mcherry-aav-serotype-8_SL101128.png?v=1770796210"},{"product_id":"aav-cag-icre-aav-serotype-8-bhv21500163","title":"AAV-CAG-iCre (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500163\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176220525,"sku":"SL101412-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176253293,"sku":"SL101412-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500163_aav-cag-icre-aav-serotype-8_SL101412.png?v=1770796230"},{"product_id":"aav-cag-flpo-aav-serotype-8-bhv21500167","title":"AAV-CAG-FLPo (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500167\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176482669,"sku":"SL101416-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176515437,"sku":"SL101416-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500167_aav-cag-flpo-aav-serotype-8_SL101416.png?v=1770796232"},{"product_id":"aav-apoe-aat1-gfp-serotype-8-bhv21500173","title":"AAV-ApoE\/AAT1-GFP (Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-ApoE\/AAT1-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eApoE\/AAT1 Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500173\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe ApoE\/AAT1 combination drives strong liver-specific expression and is used for hepatocyte-targeted gene expression studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eApoE\/AAT1-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for hepatocyte-specific expression in the liver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: ApoE\/AAT1-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176875885,"sku":"SL101428-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176908653,"sku":"SL101428-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500173_aav-apoe-aat1-gfp-serotype-8_SL101428.png?v=1770796234"},{"product_id":"aav-apoe-aat1-cre-serotype-8-bhv21500174","title":"AAV-ApoE\/AAT1-Cre (Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-ApoE\/AAT1-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eApoE\/AAT1 Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500174\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe ApoE\/AAT1 combination drives strong liver-specific expression and is used for hepatocyte-targeted gene expression studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eApoE\/AAT1-Cre is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for hepatocyte-specific expression in the liver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176941421,"sku":"SL101429-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176974189,"sku":"SL101429-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500174_aav-apoe-aat1-cre-serotype-8_SL101429.png?v=1770796234"},{"product_id":"aav-cmv-luc-aav-serotype-8-bhv21500177","title":"AAV-CMV-Luc (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-Luc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500177\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuciferase enables bioluminescence imaging for non-invasive in vivo tracking of transduction and gene expression. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177138029,"sku":"SL101432-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177170797,"sku":"SL101432-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500177_aav-cmv-luc-aav-serotype-8_SL101432.png?v=1770796235"},{"product_id":"aav-cmv-icre-aav-serotype-8-bhv21500182","title":"AAV-CMV-iCre (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500182\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177498477,"sku":"SL101438-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177531245,"sku":"SL101438-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500182_aav-cmv-icre-aav-serotype-8_SL101438.png?v=1770796237"},{"product_id":"aav-syn-icre-aav-serotype-8-bhv21500189","title":"AAV-Syn-iCre (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500189\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177957229,"sku":"SL101445-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177989997,"sku":"SL101445-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500189_aav-syn-icre-aav-serotype-8_SL101445.png?v=1770796239"},{"product_id":"aav-syn-flpo-aav-serotype-8-bhv21500195","title":"AAV-Syn-FLPo (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500195\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178350445,"sku":"SL101451-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178383213,"sku":"SL101451-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500195_aav-syn-flpo-aav-serotype-8_SL101451.png?v=1770796241"},{"product_id":"aav-cmv-flpo-aav-serotype-8-bhv21500203","title":"AAV-CMV-FLPo (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500203\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178874733,"sku":"SL101459-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178907501,"sku":"SL101459-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500203_aav-cmv-flpo-aav-serotype-8_SL101459.png?v=1770796244"},{"product_id":"aav-cmv-sacas9-u6-sgrna-scramble-aav-serotype-8-bhv21500208","title":"AAV-CMV-saCas9-U6-sgRNA(Scramble) (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-saCas9-U6-sgRNA(Scramble)\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV + U6 (dual) Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500208\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThis vector uses a dual-promoter design: CMV drives protein-coding transgene expression while U6 drives shRNA expression, enabling simultaneous gene delivery and knockdown. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003esaCas9-U6-sgRNA is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003esaCas9\u003c\/strong\u003e.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: saCas9-U6-sgRNA-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179202413,"sku":"SL101465-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179235181,"sku":"SL101465-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500208_aav-cmv-sacas9-u6-sgrna-scramble-aav-serotype-8_SL101465.png?v=1770796247"},{"product_id":"aav-apoe-aat1-null-aav-serotype-8-bhv21500212","title":"AAV-ApoE\/AAT1-Null (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-ApoE\/AAT1-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eApoE\/AAT1 Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500212\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe ApoE\/AAT1 combination drives strong liver-specific expression and is used for hepatocyte-targeted gene expression studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eApoE\/AAT1-Null is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for hepatocyte-specific expression in the liver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: ApoE\/AAT1-Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179464557,"sku":"SL101469-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179497325,"sku":"SL101469-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500212_aav-apoe-aat1-null-aav-serotype-8_SL101469.png?v=1770796247"},{"product_id":"aav-cb6-gfp-aav-serotype-8-bhv21500251","title":"AAV-CB6-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CB6-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCB6 Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500251\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCB6 is a compact hybrid promoter combining CMV enhancer with a truncated chicken beta-actin sequence, providing broad expression with reduced insert size. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCB6-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: CB6-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182053229,"sku":"SL101527-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182085997,"sku":"SL101527-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500251_aav-cb6-gfp-aav-serotype-8_SL101527.png?v=1770796262"},{"product_id":"aav-tbg-gfp-aav-serotype-8-bhv21500252","title":"AAV-TBG-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-TBG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eTBG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500252\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eTBG (thyroxine-binding globulin) provides highly specific hepatocyte expression and is a gold standard for liver-targeted gene delivery. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eTBG-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for hepatocyte-specific expression in the liver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: TBG-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182118765,"sku":"SL101528-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182151533,"sku":"SL101528-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500252_aav-tbg-gfp-aav-serotype-8_SL101528.png?v=1770796261"},{"product_id":"aav-u6-shrna-scramble-tdtomato-aav-serotype-8-bhv21500281","title":"AAV-U6-shRNA(scramble)-tdTOMATO (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-tdTOMATO\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500281\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020184215917,"sku":"SL116022-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020184248685,"sku":"SL116022-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500281_aav-u6-shrna-scramble-tdtomato-aav-serotype-8_SL116022.png?v=1770796271"},{"product_id":"aav-tbg-luc-p2a-gfp-aav-serotype-8-bhv21500307","title":"AAV-TBG-Luc-P2A-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-TBG-Luc-P2A-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eTBG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500307\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eTBG (thyroxine-binding globulin) provides highly specific hepatocyte expression and is a gold standard for liver-targeted gene delivery. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eTBG-Luc-P2A-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for hepatocyte-specific expression in the liver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: TBG-Luc-P2A-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020186018157,"sku":"SL116065-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020186050925,"sku":"SL116065-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500307_aav-tbg-luc-p2a-gfp-aav-serotype-8_SL116065.png?v=1770796281"},{"product_id":"aav-cag-fluc-aav-serotype-8-bhv21500347","title":"AAV-CAG-fLuc (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-fLuc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500347\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003efLuc is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: fLuc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020189360493,"sku":"SL116148-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020189393261,"sku":"SL116148-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500347_aav-cag-fluc-aav-serotype-8_SL116148.png?v=1770796296"},{"product_id":"aav-cag-tdtomato-aav-serotype-8-bhv21500357","title":"AAV-CAG-tdTomato (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-tdTomato\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500357\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003etdTomato is a bright red fluorescent protein with high photostability, used for long-term cell tracking.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: tdTomato-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020190409069,"sku":"SL116185-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020190441837,"sku":"SL116185-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500357_aav-cag-tdtomato-aav-serotype-8_SL116185.png?v=1770796302"},{"product_id":"aav-cag-luc-t2a-gfp-aav-serotype-8-bhv21500358","title":"AAV-CAG-Luc-T2A-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Luc-T2A-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500358\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuc-T2A-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-T2A-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020190507373,"sku":"SL116186-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020190540141,"sku":"SL116186-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500358_aav-cag-luc-t2a-gfp-aav-serotype-8_SL116186.png?v=1770796302"},{"product_id":"aav-cag-mcherry-aav-serotype-8-bhv21500359","title":"AAV-CAG-mCherry (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500359\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020190572909,"sku":"SL116192-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020190605677,"sku":"SL116192-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500359_aav-cag-mcherry-aav-serotype-8_SL116192.png?v=1770796303"},{"product_id":"aav-empty-capsid-serotype-8-bhv21500364","title":"AAV Empty Capsid (Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV Empty Capsid\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eEfficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500364\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eEmpty Capsid is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cell-type targeting not specified; verify in your model.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Empty Capsid-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 Capsid\/mL \/ 30 uL (Std Pack)","offer_id":53020191031661,"sku":"SL116199-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 Capsid\/mL \/ 10 uL (Trial Pack)","offer_id":53020191064429,"sku":"SL116199-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AAV8_Empty_Capsid.jpg?v=1779470325"},{"product_id":"aav-cmv-nanoluc-t2a-mcherry-serotype-8-bhv21500368","title":"AAV-CMV-nanoLuc-T2A-mCherry (Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-nanoLuc-T2A-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500368\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003enanoLuc-T2A-mCherry is the encoded payload for this construct. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: nanoLuc-T2A-mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020191359341,"sku":"SL116219-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020191392109,"sku":"SL116219-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500368_aav-cmv-nanoluc-t2a-mcherry-serotype-8_SL116219.png?v=1770796305"},{"product_id":"aav-hbv1-2-aav-serotype-8-bhv21500373","title":"AAV-HBV1.2 (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-HBV1.2\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eNot specified Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500373\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe promoter for this construct is not specified; refer to the product datasheet for regulatory element details. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eHBV1.2 is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cell-type targeting not specified; verify in your model.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: HBV1.2-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020191818093,"sku":"SL116257-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020191850861,"sku":"SL116257-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500373_aav-hbv1-2-aav-serotype-8_SL116257.png?v=1770796307"},{"product_id":"aav-hbv1-3-aav-serotype-8-bhv21500374","title":"AAV-HBV1.3 (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-HBV1.3\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eNot specified Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500374\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe promoter for this construct is not specified; refer to the product datasheet for regulatory element details. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eHBV1.3 is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cell-type targeting not specified; verify in your model.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: HBV1.3-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020191883629,"sku":"SL116258-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020191916397,"sku":"SL116258-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500374_aav-hbv1-3-aav-serotype-8_SL116258.png?v=1770796307"},{"product_id":"aav-cag-icre-t2a-gfp-aav-serotype-8-bhv21500382","title":"AAV-CAG-iCre-T2A-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-iCre-T2A-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500382\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre-T2A-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020192538989,"sku":"SL116277-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020192571757,"sku":"SL116277-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500382_aav-cag-icre-t2a-gfp-aav-serotype-8_SL116277.png?v=1770796310"},{"product_id":"aav-syn-luc-aav-serotype-8-bhv21500397","title":"AAV-Syn-Luc (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-Luc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500397\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuciferase enables bioluminescence imaging for non-invasive in vivo tracking of transduction and gene expression. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020193784173,"sku":"SL116346-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020193816941,"sku":"SL116346-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500397_aav-syn-luc-aav-serotype-8_SL116346.png?v=1770796315"},{"product_id":"aav-ttr-cre-aav-serotype-8-bhv21500423","title":"AAV-TTR-Cre (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-TTR-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eTTR Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500423\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eTTR (transthyretin) is a liver-specific promoter commonly used for hepatic gene delivery and protein secretion studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eTTR-Cre is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for hepatocyte-specific expression in the liver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020195684717,"sku":"SL116376-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020195717485,"sku":"SL116376-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500423_aav-ttr-cre-aav-serotype-8_SL116376.png?v=1770796325"},{"product_id":"aav-ttr-gfp-aav-serotype-8-bhv21500424","title":"AAV-TTR-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-TTR-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eTTR Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500424\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eTTR (transthyretin) is a liver-specific promoter commonly used for hepatic gene delivery and protein secretion studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eTTR-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for hepatocyte-specific expression in the liver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: TTR-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020195783021,"sku":"SL116377-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020195815789,"sku":"SL116377-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500424_aav-ttr-gfp-aav-serotype-8_SL116377.png?v=1770796325"},{"product_id":"aav-cag-nanoluc-t2a-mcherry-serotype-8-bhv21500465","title":"AAV-CAG-nanoLuc-T2A-mCherry (Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-nanoLuc-T2A-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500465\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003enanoLuc-T2A-mCherry is the encoded payload for this construct. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: nanoLuc-T2A-mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020198699373,"sku":"SL116475-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020198732141,"sku":"SL116475-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500465_aav-cag-nanoluc-t2a-mcherry-serotype-8_SL116475.png?v=1770796340"}],"url":"https:\/\/www.ebiohippo.com\/collections\/aav8-vectors.oembed","provider":"BioHippo","version":"1.0","type":"link"}